BC Platforms technology enables new personalized therapies in multiple sclerosis

January 2, 2017

BC Platforms, a world leader in genomic data management solutions, today announced that it has been selected to take part in a large global new partnership called ‘MultipleMS’. Coordinated by Karolinska Institute in Sweden, the MultipleMS consortium has been awarded 15 million euro from the European Commission in the Horizon2020 program to find novel and better treatments for Multiple Sclerosis (MS). In this project, universities and companies across 12 European countries and the US will unite efforts to tailor the development and application of therapies to the individual MS patient.

BC Platforms have been chosen to supply the technical engine for the project and will provide its software to researchers for data integration, analysis, sharing and collaboration in a secure environment. The Platform chosen for the project is based on the BC|GENOME product, and uses the BC|TILING module for super scalable data storage and analysis. In addition, BC Platforms will provide database training, maintenance and on-going user support throughout the project.

MS is an immune-mediated disease and a leading cause of non-traumatic disability in young adults in Europe, affecting over 2 million persons worldwide. MS is a highly heterogeneous disease and a cure for MS is not yet available. As the result, current treatments vary strongly from patient to patient, and predicting the specific beneficial treatment for each patient would improve disease management.

“What is truly unique about this project is the scale of the partnership and the huge amount and different kinds of patient data that will be combined. Our novel approach is to take the multifaceted nature of MS as the starting point for identifying personalized treatment opportunities in MS,” Professor Ingrid Kockum of KI, coordinator of the project, stated.

“The choice of BC technology for this challenging project combining multiple data sources of data it a testament to our successful track record in delivering results in these types of large consortium projects over the last 20 years and to the confidence researchers place in BC´s ability to deliver functional results. We are proud to have been selected for a project of this magnitude and to be able to contribute to finding treatments for this devastating disease,” said CEO Tero Silvola of BC Platforms.

The project builds on the foundations and research networks laid out by earlier consortia such as the Nordic MS genetics network, the International MS Genetics Consortium (IMSGC) and International Human Epigenome Consortium (IHEC).

“The project will combine a variety of data, such as, clinical, genetic, epigenetic, molecular, MRI and lifestyle data from more than 50,000 MS patients and 30,000 healthy individuals to elucidate differential disease characteristics in patients,” Professor Kockum says.

In parallel with the integration of the collectively available data, a sample of newly diagnosed patients will be followed longitudinally, resulting in a harmonized cohort to verify the lead findings. Based on this integrated information, the aim is that both existing and new treatments can be personalized based on characteristics and biomarkers in individual patients.

About the MultipleMS Consortium
The consortium name ‘MultipleMS’ refers to the disease Multiple Sclerosis, the multiple manifestations thereof and to the size and multiplicity of the partnership. More information can be found at the consortium website: www.multiplems.eu.

About BC Platforms
BC Platforms is a world leader in providing powerful genomic data management solutions to address some of the biggest healthcare challenges today by leveraging the convergence of genomics and healthcare information technologies. Our high performing genomic data management platform enables flexible data integration, secure analysis and interpretation of molecular and clinical information. BC Platforms’ vision is to revolutionize decision making in drug development to bring clinical benefits to patients. Founded in 1997, the Company has a strong scientific heritage underpinned by 18 years of working in close collaboration with a network of leading researchers, developers, manufacturers and vendors.
We currently provide solutions to over 50 leading international institutions in 18 countries including top-tier academic and hospital research groups, major pharmaceutical and agricultural companies.  Our management team consists of industry leaders with over 100 years of combined experience in life sciences, computational biology and industrial technology.  BC Platforms has global operations with its headquarters in Basel, Switzerland, research and development located in Helsinki, Finland, and sales and marketing based in London, Boston, and Vancouver.